Renal excretory function in patients with resistant arterial hypertension after radiofrequency kidney denervation at three-year follow-up

It is generally accepted that the true-resistant hypertension (RH) currently remains critical issue. At present there is some published evidence that catheter renal denervation prosedure showed effectiveness at randomized clinical trials. The assessment of renal function after the technique is crucial.

THE AIM of the study was to estimate renal function after renal artery denervation procedure in patients with uncontrolled hypertension in 3 – years follow-up.

PATIENTS AND METHODS. The diagnosis of RH was made in the absence of any evidence of secondary hypertension. 40 patients (20 male and и 20 female), aged 55,5± 7,2 years, with office systolic blood pressure (BP) 180 ±26,1 mm Hg, and diastolic BP 107,4±13,9 mm Hg were examined. Glomerular filtration rate (GFR, MDRD) and microalbuminuria level was determined by averaging all measurements performed during hospitalization. Ambulatory blood pressure monitoring (BPM) was performed in all patients.

RESULTS. BPM has revealed the significant decrease of systolic daytime blood pressure (at baseline 161,1±16,9 mm Hg and at follow-up 155,4±20,8 mm Hg; р= 0,024) and decrease of diastolic daytime BP (at baseline 95,6 ±11,8 mmHg and at follow -up 90,2 ±12,4 mm Hg; р=0,002). During 3 -year of follow-up the serum creatinine level has increased at baseline 69,5±16,4 μmol/l and at follow-up 78,7±19,5 μmol/l; р<0,0001). The Glomerular filtration rate has scaled down (at baseline 98,2±18,7 ml/min and at follow-up 85,1±17,9 ml/min; р< 0,0001). The level of daily excretion of albumin has also decreased (at baseline 30,4 [14,6; 52,9] mg and at follow-up 14,1 [11,9; 42,4] mg correspondingly; р= 0,03) .

CONCLUSION. Although BP profile changes have demonstrated the effectiveness of RDN, therefore the future investigation of exact patho-physiological significance of glomerular filtration level after the treatment of RH should be of provided.

1. Williams B, Mancia G, Spiering W et al. Authors/Task Force Members. 2018 ESC/ESH Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens 2018; 36:1953–2041. doi: 10.1097/HJH.0000000000001940

2. Samorodskaya IV, Semenov V YU. Mortality from arterial hypertension in the regions of the Russian Federation in the period from 2013 to 2019. Cardiology 2021;61(12):59–65 (In Russ.) doi: 10.18087/cardio.2021.12.n1643

3. Pekarski SE, Mordovin VF, Ripp TM, Falkovskaya AY. Intervention treatment of arterial hypertension: the effective optimization of renal artery denervation. Milon Company, Tomsk, 2017:222 p. (In Russ.)

4. Siddiqui M, Calhoun DA. Refractory versus resistant hypertension. Curr Opin Nephrol Hypertens 2017 Jan;26(1):14–19. doi: 10.1097/MNH.0000000000000286. PMID: 27798457

5. Danilov NicN, Agaeva RegA, Matchin YuG et al. Russian medical society on arterial hypertension (RMSAH) consensus of experts on the use of radiofrequency denervation of the renal arteries in patients with arterial hypertension. Systemic hypertensions 2017;17 (4):7–18. (In Russ.) doi: 10.26442/2075082X.2020.4.200398

6. Danilov NM, Matchin IuG, Chazova IE. Endovascular radiofrequency denervation of renal arteries as an innovation method of treatment of refractory arterial hypertension. First experience in Russia. Angiol Sosud Khir 2012;18(1):51–54. (In Russ.) PMID: 22836328

7. Townsend RR, Mahfoud F, Kandzari DE et al. SPYRAL HTN-OFF MED trial investigators. Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. Lancet 2017; 11(10108):2160–2170. doi: 10.1016/S0140-6736(17)32281-X

8. Blood Pressure Lowering Treatment Trialists' Collaboration. Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis. Lancet 2021 May 1; 397(10285):1625–1636. doi: 10.1016/S0140-6736(21)00590-0. PMID: 33933205; PMCID: PMC8102467

9. Agaeva RA, Danilov NM, Shelkova GV et al. New opportunities of renal denervation]. Ter Arkh 2020 92(6):84–88. (In Russ.) doi: 10.26442/00403660.2020.06.000588

10. Helmersson-Karlqvist J, Lipcsey M, Ärnlöv J et al. Cystatin C predicts long term mortality better than creatinine in a nationwide study of intensive care patients. Sci Rep 2021 Mar 15;11(1):5882. doi: 10.1038/s41598-021-85370-8

11. Webster AC, Nagler EV, Morton RL, Masson P. Chronic Kidney Disease. Lancet 2017 Mar 25;389(10075):1238–1252. doi: 10.1016/S0140-6736(16)32064-5

12. Boddi M. Renal Ultrasound (and Doppler Sonography) in Hypertension: An Update. Adv Exp Med Biol 2017;956:191–208. doi: 10.1007/5584_2016_170

13. Arai H, Sato Y, Yanagita M. Fibroblast heterogeneity and tertiary lymphoid tissues in the kidney. Immunol Rev 2021 Jul;302(1):196–210. doi: 10.1111/imr.12969

14. Gapon LI, Mikova EV, Savelyeva NY et al. Clinical efficacy of sympathetic denervation of renal arteries in patients with resistant arterial hypertension as part of annual prospective follow up. Systemic Hypertension 2017;14:(2):41–44. (In Russ.) doi: 10.26442/SG29185